Coherus Oncology (CHRS) Capital Expenditures Growth (3y) (2016 - 2025)
Coherus Oncology (CHRS) Capital Expenditures Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -45.93% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -40.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 29.63% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 19.18% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.08% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 60.74% |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 358.32% |
| Jun 30, 2025 | -719.98% |
| Mar 31, 2025 | 97.24% |
| Jun 30, 2024 | -361.65% |
| Mar 31, 2024 | -990.65% |
| Dec 31, 2023 | -67.07% |
| Jun 30, 2023 | -65.25% |
| Mar 31, 2023 | -55.99% |
| Dec 31, 2022 | -59.63% |
| Sep 30, 2022 | 206.82% |
| Jun 30, 2022 | 69.10% |
| Mar 31, 2022 | 22.45% |
| Dec 31, 2021 | 676.39% |
| Sep 30, 2021 | 71.39% |
| Jun 30, 2021 | 336.21% |
| Mar 31, 2021 | 21.42% |
| Dec 31, 2020 | 30.32% |
| Sep 30, 2020 | 5.24% |
| Jun 30, 2020 | 35.37% |
| Mar 31, 2020 | 1.78% |